Front-line daratumumab-VTd versus standard-of-care in ASCT-eligible multiple myeloma: matching-adjusted indirect comparison.

@article{Moreau2020FrontlineDV,
  title={Front-line daratumumab-VTd versus standard-of-care in ASCT-eligible multiple myeloma: matching-adjusted indirect comparison.},
  author={P. Moreau and B. H{\'e}braud and T. Façon and X. Leleu and C. Hulin and M. Hashim and Yannan Hu and D. Caillot and L. Benboubker and S. Zweegman and M. Merz and K. Weisel and H. Salwender and E. K. Mai and H. Goldschmidt and U. Bertsch and V. Vanquickelberghe and Tobias Kampfenkel and C. Boer and S. Krotneva and I. Proskorovsky and J. He and A. Lam and C. Lee and S. C{\^o}t{\'e} and P. Sonneveld},
  journal={Immunotherapy},
  year={2020}
}
Aim: To compare daratumumab plus standard-of-care (SoC; bortezomib/thalidomide/dexamethasone [VTd]) and VTd alone with other SoC for transplant-eligible newly diagnosed multiple myeloma. Patients & methods: We conducted an unanchored matching-adjusted indirect comparison of progression-free and overall survival (PFS/OS) with D-VTd/VTd versus bortezomib/lenalidomide/dexamethasone (VRd), bortezomib/cyclophosphamide/dexamethasone (VCd) and bortezomib/dexamethasone (Vd). Results: After matching… Expand

References

SHOWING 1-10 OF 29 REFERENCES
...
1
2
3
...